DS-9231 in Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)

Summary

The primary objective of this study is to evaluate safety and initial effectiveness of DS-9231 when taken together with current standard of care. Evaluation will be done with low, medium and then high doses of DS-9231 versus placebo, in participants with medium-risk acute pulmonary embolism.

Timeline

Start

2018-01

Primary completion

2020-02

Completion

2020-02

Outcome

Outcome not reported

Stopped: “Product development cancelled.”

Drugs

Indications